{"product_id":"international-myeloma-society-educational-workshop-in-belgrade-serbia-2026","title":"International Myeloma Society Educational Workshop in Belgrade, Serbia 2026","description":"\u003cdiv id=\"bylineInfo\" class=\"a-section a-spacing-micro bylineHidden feature\"\u003e\r\n\u003ch1\u003eInternational Myeloma Society Educational Workshop – Belgrade, Serbia 2026 (Videos)\u003c\/h1\u003e\r\n\u003ch2\u003eComprehensive Updates in Multiple Myeloma, Plasma Cell Disorders, MRD Testing, CAR T-Cell Therapy, Bispecific Antibodies, AL Amyloidosis, Waldenström Macroglobulinemia, and Precision Hematologic Oncology\u003c\/h2\u003e\r\n\u003cp class=\"isSelectedEnd\"\u003eStay at the forefront of plasma cell malignancy management with the \u003cstrong\u003eInternational Myeloma Society Educational Workshop – Belgrade, Serbia 2026\u003c\/strong\u003e, a world-class continuing medical education (CME) event organized by the \u003cstrong\u003eInternational Myeloma Society (IMS)\u003c\/strong\u003e in collaboration with the \u003cstrong\u003eBalkan Myeloma Study Group\u003c\/strong\u003e and the \u003cstrong\u003eSerbian Myeloma Group\u003c\/strong\u003e. This highly specialized educational workshop brings together internationally recognized experts to present the latest scientific advances, evidence-based treatment strategies, and emerging therapeutic innovations in multiple myeloma and related plasma cell disorders.\u003c\/p\u003e\r\n\u003cp class=\"isSelectedEnd\"\u003eHeld \u003cstrong\u003eMarch 13–14, 2026\u003c\/strong\u003e, in \u003cstrong\u003eBelgrade, Serbia\u003c\/strong\u003e, the workshop features expert lectures, multidisciplinary roundtable discussions, point-counterpoint debates, and challenging clinical case reviews designed to address the most important developments in diagnostic evaluation, risk stratification, measurable residual disease (MRD), immunotherapy, cellular therapy, supportive care, and personalized treatment planning.\u003c\/p\u003e\r\n\u003cp class=\"isSelectedEnd\"\u003eDesigned for hematologists and oncologists managing patients with plasma cell malignancies, this comprehensive program provides practical guidance on integrating rapidly evolving therapies—including \u003cstrong\u003eCAR T-cell therapy\u003c\/strong\u003e, \u003cstrong\u003eBispecific T-cell Engagers (BiTEs)\u003c\/strong\u003e, novel immunotherapies, and precision medicine—into everyday clinical practice.\u003c\/p\u003e\r\n\r\n\u003cdiv contenteditable=\"false\"\u003e\r\n\r\n\u003chr\u003e\r\n\r\n\u003c\/div\u003e\r\n\u003ch1\u003eProduct Details\u003c\/h1\u003e\r\n\u003cul data-spread=\"false\"\u003e\r\n \t\u003cli\u003e\n\u003cstrong\u003eCourse:\u003c\/strong\u003e International Myeloma Society Educational Workshop – Belgrade, Serbia 2026\u003c\/li\u003e\r\n \t\u003cli\u003e\n\u003cstrong\u003eProvider:\u003c\/strong\u003e International Myeloma Society (IMS)\u003c\/li\u003e\r\n \t\u003cli\u003e\n\u003cstrong\u003eCollaborating Organizations:\u003c\/strong\u003e Balkan Myeloma Study Group \u0026amp; Serbian Myeloma Group\u003c\/li\u003e\r\n \t\u003cli\u003e\n\u003cstrong\u003eConference Dates:\u003c\/strong\u003e March 13–14, 2026\u003c\/li\u003e\r\n \t\u003cli\u003e\n\u003cstrong\u003eLocation:\u003c\/strong\u003e Belgrade, Serbia\u003c\/li\u003e\r\n \t\u003cli\u003e\n\u003cstrong\u003eFormat:\u003c\/strong\u003e Videos\u003c\/li\u003e\r\n \t\u003cli\u003e\n\u003cstrong\u003eLanguage:\u003c\/strong\u003e English\u003c\/li\u003e\r\n \t\u003cli\u003e\n\u003cstrong\u003eEducational Level:\u003c\/strong\u003e Advanced\u003c\/li\u003e\r\n \t\u003cli\u003e\n\u003cstrong\u003eLearning Format:\u003c\/strong\u003e Expert Lectures, Roundtable Discussions, Point-Counterpoint Sessions, Clinical Case Reviews\u003c\/li\u003e\r\n\u003c\/ul\u003e\r\n\u003cdiv contenteditable=\"false\"\u003e\r\n\r\n\u003chr\u003e\r\n\r\n\u003c\/div\u003e\r\n\u003ch1\u003eCourse Overview\u003c\/h1\u003e\r\n\u003cp class=\"isSelectedEnd\"\u003eThe treatment landscape for \u003cstrong\u003eMultiple Myeloma\u003c\/strong\u003e has evolved dramatically with advances in molecular diagnostics, measurable residual disease (MRD) assessment, immunotherapy, cellular therapies, targeted agents, and personalized treatment strategies. Clinicians must continually adapt to emerging evidence regarding disease biology, risk stratification, sequencing of therapies, and management of increasingly complex clinical scenarios.\u003c\/p\u003e\r\n\u003cp class=\"isSelectedEnd\"\u003eThe \u003cstrong\u003eInternational Myeloma Society Educational Workshop 2026\u003c\/strong\u003e provides a comprehensive review of contemporary plasma cell malignancy management. International leaders in hematology discuss updated diagnostic criteria, advanced imaging, transplant decision-making, novel immunotherapies, relapse management, supportive care, and evolving treatment algorithms for patients across every stage of multiple myeloma.\u003c\/p\u003e\r\n\u003cp class=\"isSelectedEnd\"\u003eSpecial emphasis is placed on integrating MRD-guided treatment, CAR T-cell therapy, bispecific antibodies, frailty assessment, supportive care, and multidisciplinary management to improve survival, quality of life, and long-term patient outcomes.\u003c\/p\u003e\r\n\r\n\u003cdiv contenteditable=\"false\"\u003e\r\n\r\n\u003chr\u003e\r\n\r\n\u003c\/div\u003e\r\n\u003ch1\u003eWhat You'll Learn\u003c\/h1\u003e\r\n\u003cp class=\"isSelectedEnd\"\u003eAfter completing this course, participants will be able to:\u003c\/p\u003e\r\n\r\n\u003cul data-spread=\"false\"\u003e\r\n \t\u003cli\u003eApply updated diagnostic criteria and imaging techniques for multiple myeloma.\u003c\/li\u003e\r\n \t\u003cli\u003eIntegrate measurable residual disease (MRD) testing into treatment planning.\u003c\/li\u003e\r\n \t\u003cli\u003eUtilize contemporary risk stratification models for smoldering and newly diagnosed multiple myeloma.\u003c\/li\u003e\r\n \t\u003cli\u003eDevelop evidence-based treatment strategies for transplant-eligible and transplant-ineligible patients.\u003c\/li\u003e\r\n \t\u003cli\u003eOptimize sequencing of therapies for relapsed and refractory multiple myeloma.\u003c\/li\u003e\r\n \t\u003cli\u003eIncorporate CAR T-cell therapy and bispecific antibodies into clinical practice.\u003c\/li\u003e\r\n \t\u003cli\u003eManage complications including bone disease, renal impairment, infections, and treatment-related toxicities.\u003c\/li\u003e\r\n \t\u003cli\u003eDiagnose and treat related plasma cell disorders including AL amyloidosis and Waldenström macroglobulinemia.\u003c\/li\u003e\r\n\u003c\/ul\u003e\r\n\u003cdiv contenteditable=\"false\"\u003e\r\n\r\n\u003chr\u003e\r\n\r\n\u003c\/div\u003e\r\n\u003ch1\u003eComprehensive Topics Covered\u003c\/h1\u003e\r\n\u003ch2\u003eMultiple Myeloma Diagnosis\u003c\/h2\u003e\r\n\u003cp class=\"isSelectedEnd\"\u003eStrengthen diagnostic accuracy using current international standards.\u003c\/p\u003e\r\n\u003cp class=\"isSelectedEnd\"\u003eTopics include:\u003c\/p\u003e\r\n\r\n\u003cul data-spread=\"false\"\u003e\r\n \t\u003cli\u003eMultiple myeloma diagnosis\u003c\/li\u003e\r\n \t\u003cli\u003eLaboratory evaluation\u003c\/li\u003e\r\n \t\u003cli\u003eBone marrow assessment\u003c\/li\u003e\r\n \t\u003cli\u003eCytogenetics\u003c\/li\u003e\r\n \t\u003cli\u003eAdvanced imaging\u003c\/li\u003e\r\n \t\u003cli\u003eDisease staging\u003c\/li\u003e\r\n \t\u003cli\u003eDiagnostic criteria\u003c\/li\u003e\r\n\u003c\/ul\u003e\r\n\u003cp class=\"isSelectedEnd\"\u003eFaculty review the latest recommendations for early diagnosis and comprehensive disease evaluation.\u003c\/p\u003e\r\n\r\n\u003cdiv contenteditable=\"false\"\u003e\r\n\r\n\u003chr\u003e\r\n\r\n\u003c\/div\u003e\r\n\u003ch2\u003eMeasurable Residual Disease (MRD)\u003c\/h2\u003e\r\n\u003cp class=\"isSelectedEnd\"\u003eIntegrate MRD assessment into precision treatment planning.\u003c\/p\u003e\r\n\u003cp class=\"isSelectedEnd\"\u003eTopics include:\u003c\/p\u003e\r\n\r\n\u003cul data-spread=\"false\"\u003e\r\n \t\u003cli\u003eMeasurable residual disease (MRD)\u003c\/li\u003e\r\n \t\u003cli\u003eMRD testing\u003c\/li\u003e\r\n \t\u003cli\u003eFlow cytometry\u003c\/li\u003e\r\n \t\u003cli\u003eNext-generation sequencing\u003c\/li\u003e\r\n \t\u003cli\u003eResponse assessment\u003c\/li\u003e\r\n \t\u003cli\u003ePrognostic value\u003c\/li\u003e\r\n \t\u003cli\u003eTreatment monitoring\u003c\/li\u003e\r\n\u003c\/ul\u003e\r\n\u003cdiv contenteditable=\"false\"\u003e\r\n\r\n\u003chr\u003e\r\n\r\n\u003c\/div\u003e\r\n\u003ch2\u003eRisk Stratification\u003c\/h2\u003e\r\n\u003cp class=\"isSelectedEnd\"\u003eImprove individualized treatment selection.\u003c\/p\u003e\r\n\u003cp class=\"isSelectedEnd\"\u003eTopics include:\u003c\/p\u003e\r\n\r\n\u003cul data-spread=\"false\"\u003e\r\n \t\u003cli\u003eHigh-risk myeloma\u003c\/li\u003e\r\n \t\u003cli\u003eCytogenetic abnormalities\u003c\/li\u003e\r\n \t\u003cli\u003eMolecular profiling\u003c\/li\u003e\r\n \t\u003cli\u003eRisk-adapted therapy\u003c\/li\u003e\r\n \t\u003cli\u003ePrognostic biomarkers\u003c\/li\u003e\r\n \t\u003cli\u003ePersonalized medicine\u003c\/li\u003e\r\n \t\u003cli\u003eClinical decision-making\u003c\/li\u003e\r\n\u003c\/ul\u003e\r\n\u003cdiv contenteditable=\"false\"\u003e\r\n\r\n\u003chr\u003e\r\n\r\n\u003c\/div\u003e\r\n\u003ch2\u003eSmoldering Multiple Myeloma\u003c\/h2\u003e\r\n\u003cp class=\"isSelectedEnd\"\u003eReview current management strategies for early disease.\u003c\/p\u003e\r\n\u003cp class=\"isSelectedEnd\"\u003eTopics include:\u003c\/p\u003e\r\n\r\n\u003cul data-spread=\"false\"\u003e\r\n \t\u003cli\u003eSmoldering myeloma\u003c\/li\u003e\r\n \t\u003cli\u003eDisease progression\u003c\/li\u003e\r\n \t\u003cli\u003eEarly intervention\u003c\/li\u003e\r\n \t\u003cli\u003eObservation strategies\u003c\/li\u003e\r\n \t\u003cli\u003eRisk prediction\u003c\/li\u003e\r\n \t\u003cli\u003eClinical trials\u003c\/li\u003e\r\n \t\u003cli\u003ePreventive treatment\u003c\/li\u003e\r\n\u003c\/ul\u003e\r\n\u003cdiv contenteditable=\"false\"\u003e\r\n\r\n\u003chr\u003e\r\n\r\n\u003c\/div\u003e\r\n\u003ch2\u003eNewly Diagnosed Multiple Myeloma\u003c\/h2\u003e\r\n\u003cp class=\"isSelectedEnd\"\u003eMaster evidence-based frontline therapy.\u003c\/p\u003e\r\n\u003cp class=\"isSelectedEnd\"\u003eTopics include:\u003c\/p\u003e\r\n\r\n\u003cul data-spread=\"false\"\u003e\r\n \t\u003cli\u003eNewly diagnosed multiple myeloma\u003c\/li\u003e\r\n \t\u003cli\u003eInduction therapy\u003c\/li\u003e\r\n \t\u003cli\u003eStem cell transplantation\u003c\/li\u003e\r\n \t\u003cli\u003eMaintenance therapy\u003c\/li\u003e\r\n \t\u003cli\u003eTransplant eligibility\u003c\/li\u003e\r\n \t\u003cli\u003eNon-transplant management\u003c\/li\u003e\r\n \t\u003cli\u003eFirst-line treatment\u003c\/li\u003e\r\n\u003c\/ul\u003e\r\n\u003cp class=\"isSelectedEnd\"\u003eFaculty discuss individualized treatment pathways based on patient characteristics and disease biology.\u003c\/p\u003e\r\n\r\n\u003cdiv contenteditable=\"false\"\u003e\r\n\r\n\u003chr\u003e\r\n\r\n\u003c\/div\u003e\r\n\u003ch2\u003eRelapsed \u0026amp; Refractory Multiple Myeloma\u003c\/h2\u003e\r\n\u003cp class=\"isSelectedEnd\"\u003eOptimize sequencing of increasingly complex therapies.\u003c\/p\u003e\r\n\u003cp class=\"isSelectedEnd\"\u003eTopics include:\u003c\/p\u003e\r\n\r\n\u003cul data-spread=\"false\"\u003e\r\n \t\u003cli\u003eRelapsed multiple myeloma\u003c\/li\u003e\r\n \t\u003cli\u003eRefractory disease\u003c\/li\u003e\r\n \t\u003cli\u003eTreatment sequencing\u003c\/li\u003e\r\n \t\u003cli\u003eTriple-class refractory disease\u003c\/li\u003e\r\n \t\u003cli\u003eSalvage therapy\u003c\/li\u003e\r\n \t\u003cli\u003eClinical decision-making\u003c\/li\u003e\r\n \t\u003cli\u003eEmerging agents\u003c\/li\u003e\r\n\u003c\/ul\u003e\r\n\u003cdiv contenteditable=\"false\"\u003e\r\n\r\n\u003chr\u003e\r\n\r\n\u003c\/div\u003e\r\n\u003ch2\u003eCellular \u0026amp; Immune Therapies\u003c\/h2\u003e\r\n\u003cp class=\"isSelectedEnd\"\u003eExplore revolutionary advances in immunotherapy.\u003c\/p\u003e\r\n\u003cp class=\"isSelectedEnd\"\u003eTopics include:\u003c\/p\u003e\r\n\r\n\u003cul data-spread=\"false\"\u003e\r\n \t\u003cli\u003eCAR T-cell therapy\u003c\/li\u003e\r\n \t\u003cli\u003eBispecific T-cell Engagers (BiTEs)\u003c\/li\u003e\r\n \t\u003cli\u003eImmune-based therapy\u003c\/li\u003e\r\n \t\u003cli\u003eCellular immunotherapy\u003c\/li\u003e\r\n \t\u003cli\u003eT-cell redirection\u003c\/li\u003e\r\n \t\u003cli\u003eImmune toxicity\u003c\/li\u003e\r\n \t\u003cli\u003eNovel immunotherapeutics\u003c\/li\u003e\r\n\u003c\/ul\u003e\r\n\u003cp class=\"isSelectedEnd\"\u003eParticipants review patient selection, efficacy, toxicity management, and future directions.\u003c\/p\u003e\r\n\r\n\u003cdiv contenteditable=\"false\"\u003e\r\n\r\n\u003chr\u003e\r\n\r\n\u003c\/div\u003e\r\n\u003ch2\u003eSupportive Care\u003c\/h2\u003e\r\n\u003cp class=\"isSelectedEnd\"\u003eImprove quality of life through comprehensive supportive management.\u003c\/p\u003e\r\n\u003cp class=\"isSelectedEnd\"\u003eTopics include:\u003c\/p\u003e\r\n\r\n\u003cul data-spread=\"false\"\u003e\r\n \t\u003cli\u003eBone disease\u003c\/li\u003e\r\n \t\u003cli\u003eBisphosphonates\u003c\/li\u003e\r\n \t\u003cli\u003eRenal failure\u003c\/li\u003e\r\n \t\u003cli\u003eInfection prevention\u003c\/li\u003e\r\n \t\u003cli\u003eVaccination\u003c\/li\u003e\r\n \t\u003cli\u003eSupportive oncology\u003c\/li\u003e\r\n \t\u003cli\u003eSymptom management\u003c\/li\u003e\r\n\u003c\/ul\u003e\r\n\u003cdiv contenteditable=\"false\"\u003e\r\n\r\n\u003chr\u003e\r\n\r\n\u003c\/div\u003e\r\n\u003ch2\u003ePlasma Cell Disorders Beyond Multiple Myeloma\u003c\/h2\u003e\r\n\u003cp class=\"isSelectedEnd\"\u003eExpand expertise in related hematologic diseases.\u003c\/p\u003e\r\n\u003cp class=\"isSelectedEnd\"\u003eTopics include:\u003c\/p\u003e\r\n\r\n\u003cul data-spread=\"false\"\u003e\r\n \t\u003cli\u003eWaldenström macroglobulinemia\u003c\/li\u003e\r\n \t\u003cli\u003eAL amyloidosis\u003c\/li\u003e\r\n \t\u003cli\u003eMonoclonal gammopathies\u003c\/li\u003e\r\n \t\u003cli\u003ePlasma cell dyscrasias\u003c\/li\u003e\r\n \t\u003cli\u003eRare plasma cell disorders\u003c\/li\u003e\r\n \t\u003cli\u003eDisease-specific management\u003c\/li\u003e\r\n \t\u003cli\u003eEmerging therapies\u003c\/li\u003e\r\n\u003c\/ul\u003e\r\n\u003cdiv contenteditable=\"false\"\u003e\r\n\r\n\u003chr\u003e\r\n\r\n\u003c\/div\u003e\r\n\u003ch2\u003eChallenging Clinical Scenarios\u003c\/h2\u003e\r\n\u003cp class=\"isSelectedEnd\"\u003eAddress complex cases encountered in modern practice.\u003c\/p\u003e\r\n\u003cp class=\"isSelectedEnd\"\u003eTopics include:\u003c\/p\u003e\r\n\r\n\u003cul data-spread=\"false\"\u003e\r\n \t\u003cli\u003eExtramedullary disease\u003c\/li\u003e\r\n \t\u003cli\u003eRelapse after CAR T-cell therapy\u003c\/li\u003e\r\n \t\u003cli\u003ePost-bispecific relapse\u003c\/li\u003e\r\n \t\u003cli\u003eFrailty assessment\u003c\/li\u003e\r\n \t\u003cli\u003eElderly patients\u003c\/li\u003e\r\n \t\u003cli\u003ePersonalized treatment algorithms\u003c\/li\u003e\r\n \t\u003cli\u003eDifficult clinical cases\u003c\/li\u003e\r\n\u003c\/ul\u003e\r\n\u003cdiv contenteditable=\"false\"\u003e\r\n\r\n\u003chr\u003e\r\n\r\n\u003c\/div\u003e\r\n\u003ch2\u003eEmerging Research \u0026amp; Future Therapies\u003c\/h2\u003e\r\n\u003cp class=\"isSelectedEnd\"\u003eReview innovations shaping the future of myeloma care.\u003c\/p\u003e\r\n\u003cp class=\"isSelectedEnd\"\u003eTopics include:\u003c\/p\u003e\r\n\r\n\u003cul data-spread=\"false\"\u003e\r\n \t\u003cli\u003eNovel targeted therapies\u003c\/li\u003e\r\n \t\u003cli\u003ePrecision oncology\u003c\/li\u003e\r\n \t\u003cli\u003eClinical trials\u003c\/li\u003e\r\n \t\u003cli\u003eNext-generation immunotherapy\u003c\/li\u003e\r\n \t\u003cli\u003eCombination strategies\u003c\/li\u003e\r\n \t\u003cli\u003eFuture treatment paradigms\u003c\/li\u003e\r\n \t\u003cli\u003eTranslational research\u003c\/li\u003e\r\n\u003c\/ul\u003e\r\n\u003cdiv contenteditable=\"false\"\u003e\r\n\r\n\u003chr\u003e\r\n\r\n\u003c\/div\u003e\r\n\u003ch1\u003eLearning Objectives\u003c\/h1\u003e\r\n\u003cp class=\"isSelectedEnd\"\u003eUpon completion of this educational activity, participants will be able to:\u003c\/p\u003e\r\n\r\n\u003cul data-spread=\"false\"\u003e\r\n \t\u003cli\u003eImplement updated diagnostic testing, imaging techniques, and measurable residual disease (MRD) assessment for multiple myeloma.\u003c\/li\u003e\r\n \t\u003cli\u003eApply contemporary risk stratification models for smoldering and newly diagnosed multiple myeloma.\u003c\/li\u003e\r\n \t\u003cli\u003eDevelop evidence-based treatment strategies for transplant-eligible and transplant-ineligible patients.\u003c\/li\u003e\r\n \t\u003cli\u003eOptimize sequencing of therapies for relapsed and refractory multiple myeloma.\u003c\/li\u003e\r\n \t\u003cli\u003eIncorporate novel immunotherapies including CAR T-cell therapy and bispecific T-cell engagers into clinical practice.\u003c\/li\u003e\r\n \t\u003cli\u003eManage myeloma-related complications including bone disease, renal impairment, infections, and supportive care needs.\u003c\/li\u003e\r\n \t\u003cli\u003eDiagnose and manage AL amyloidosis, Waldenström macroglobulinemia, and other plasma cell disorders.\u003c\/li\u003e\r\n \t\u003cli\u003eAddress challenging clinical situations including relapse after T-cell–redirected therapies, extramedullary disease, and frailty-based treatment decisions.\u003c\/li\u003e\r\n\u003c\/ul\u003e\r\n\u003cdiv contenteditable=\"false\"\u003e\r\n\r\n\u003chr\u003e\r\n\r\n\u003c\/div\u003e\r\n\u003ch1\u003eEducational Highlights\u003c\/h1\u003e\r\n\u003cul data-spread=\"false\"\u003e\r\n \t\u003cli\u003eMultiple Myeloma\u003c\/li\u003e\r\n \t\u003cli\u003ePlasma Cell Disorders\u003c\/li\u003e\r\n \t\u003cli\u003eMeasurable Residual Disease (MRD)\u003c\/li\u003e\r\n \t\u003cli\u003eCAR T-Cell Therapy\u003c\/li\u003e\r\n \t\u003cli\u003eBispecific Antibodies\u003c\/li\u003e\r\n \t\u003cli\u003eImmunotherapy\u003c\/li\u003e\r\n \t\u003cli\u003eStem Cell Transplantation\u003c\/li\u003e\r\n \t\u003cli\u003eRelapsed \u0026amp; Refractory Multiple Myeloma\u003c\/li\u003e\r\n \t\u003cli\u003eSmoldering Multiple Myeloma\u003c\/li\u003e\r\n \t\u003cli\u003eRisk Stratification\u003c\/li\u003e\r\n \t\u003cli\u003ePrecision Hematology\u003c\/li\u003e\r\n \t\u003cli\u003eWaldenström Macroglobulinemia\u003c\/li\u003e\r\n \t\u003cli\u003eAL Amyloidosis\u003c\/li\u003e\r\n \t\u003cli\u003eBone Disease\u003c\/li\u003e\r\n \t\u003cli\u003eSupportive Oncology\u003c\/li\u003e\r\n \t\u003cli\u003eHematologic Malignancies\u003c\/li\u003e\r\n \t\u003cli\u003ePlasma Cell Dyscrasias\u003c\/li\u003e\r\n \t\u003cli\u003eCellular Therapy\u003c\/li\u003e\r\n \t\u003cli\u003eHematologic Oncology\u003c\/li\u003e\r\n \t\u003cli\u003eContinuing Medical Education (CME)\u003c\/li\u003e\r\n\u003c\/ul\u003e\r\n\u003cdiv contenteditable=\"false\"\u003e\r\n\r\n\u003chr\u003e\r\n\r\n\u003c\/div\u003e\r\n\u003ch1\u003eWhy This Course Stands Out\u003c\/h1\u003e\r\n\u003cp class=\"isSelectedEnd\"\u003eThe \u003cstrong\u003eInternational Myeloma Society Educational Workshop – Belgrade 2026\u003c\/strong\u003e is one of the premier international educational events dedicated exclusively to plasma cell malignancies. Led by globally recognized experts from the International Myeloma Society, the workshop delivers cutting-edge updates on disease biology, MRD-guided therapy, advanced immunotherapies, cellular treatments, supportive care, and personalized treatment sequencing. Its interactive debates, multidisciplinary discussions, and complex clinical case reviews provide participants with practical strategies that can immediately enhance patient care in modern hematologic oncology.\u003c\/p\u003e\r\n\r\n\u003cdiv contenteditable=\"false\"\u003e\r\n\r\n\u003chr\u003e\r\n\r\n\u003c\/div\u003e\r\n\u003ch1\u003eTarget Audience\u003c\/h1\u003e\r\n\u003cp class=\"isSelectedEnd\"\u003eThis educational activity is ideal for:\u003c\/p\u003e\r\n\r\n\u003cul data-spread=\"false\"\u003e\r\n \t\u003cli\u003eHematologists\u003c\/li\u003e\r\n \t\u003cli\u003eMedical Oncologists\u003c\/li\u003e\r\n \t\u003cli\u003eHematologic Oncologists\u003c\/li\u003e\r\n \t\u003cli\u003eBone Marrow Transplant Physicians\u003c\/li\u003e\r\n \t\u003cli\u003eCellular Therapy Specialists\u003c\/li\u003e\r\n \t\u003cli\u003eClinical Hematology Fellows\u003c\/li\u003e\r\n \t\u003cli\u003eMedical Oncology Fellows\u003c\/li\u003e\r\n \t\u003cli\u003eInternal Medicine Physicians with Hematology Interest\u003c\/li\u003e\r\n \t\u003cli\u003eOncology Pharmacists\u003c\/li\u003e\r\n \t\u003cli\u003eOncology Nurse Practitioners\u003c\/li\u003e\r\n \t\u003cli\u003ePhysician Assistants specializing in Hematology\/Oncology\u003c\/li\u003e\r\n \t\u003cli\u003eClinical Researchers\u003c\/li\u003e\r\n \t\u003cli\u003eHealthcare Professionals involved in the diagnosis and treatment of plasma cell malignancies\u003c\/li\u003e\r\n\u003c\/ul\u003e\r\n\u003cdiv contenteditable=\"false\"\u003e\r\n\r\n\u003chr\u003e\r\n\r\n\u003c\/div\u003e\r\n\u003ch1\u003eWhy Choose This Course?\u003c\/h1\u003e\r\nWhether you specialize in hematology, medical oncology, bone marrow transplantation, or cellular therapy, the \u003cstrong\u003eInternational Myeloma Society Educational Workshop 2026\u003c\/strong\u003e provides one of the most comprehensive and up-to-date educational experiences in multiple myeloma and plasma cell disorders. Through internationally recognized faculty, evidence-based lectures, interactive debates, and challenging case discussions, participants gain the expertise needed to integrate novel immunotherapies, optimize treatment sequencing, improve supportive care, and deliver precision medicine for patients with plasma cell malignancies.\r\n\u003cp data-path-to-node=\"4\"\u003e\u003cb data-path-to-node=\"4\" data-index-in-node=\"0\"\u003eTopics\u003c\/b\u003e\u003c\/p\u003e\r\n\r\n\u003cul data-path-to-node=\"5\"\u003e\r\n \t\u003cli\u003e\r\n\u003cp data-path-to-node=\"5,0,0\"\u003e\u003cb data-path-to-node=\"5,0,0\" data-index-in-node=\"0\"\u003ePlenary Talks:\u003c\/b\u003e\u003c\/p\u003e\r\n\r\n\u003cul data-path-to-node=\"5,0,1\"\u003e\r\n \t\u003cli\u003e\r\n\u003cp id=\"p-rc_2abbedc5541507de-170\" data-path-to-node=\"5,0,1,0,0\"\u003e\u003cspan data-path-to-node=\"5,0,1,0,0,0\"\u003eFrom Biology to Therapy: The Current Landscape of Multiple Myeloma\u003c\/span\u003e\u003cspan data-path-to-node=\"5,0,1,0,0,2\"\u003e.\u003c\/span\u003e\u003c\/p\u003e\r\n\u003c\/li\u003e\r\n \t\u003cli\u003e\r\n\u003cp id=\"p-rc_2abbedc5541507de-171\" data-path-to-node=\"5,0,1,1,0\"\u003e\u003cspan data-path-to-node=\"5,0,1,1,0,0\"\u003eThe Future of Multiple Myeloma\u003c\/span\u003e\u003cspan data-path-to-node=\"5,0,1,1,0,2\"\u003e.\u003c\/span\u003e\u003c\/p\u003e\r\n\u003c\/li\u003e\r\n\u003c\/ul\u003e\r\n\u003c\/li\u003e\r\n \t\u003cli\u003e\r\n\u003cp data-path-to-node=\"5,1,0\"\u003e\u003cb data-path-to-node=\"5,1,0\" data-index-in-node=\"0\"\u003eDiagnosis, Risk Stratification, and Monitoring of Plasma Cell Disorders:\u003c\/b\u003e\u003c\/p\u003e\r\n\r\n\u003cul data-path-to-node=\"5,1,1\"\u003e\r\n \t\u003cli\u003e\r\n\u003cp id=\"p-rc_2abbedc5541507de-172\" data-path-to-node=\"5,1,1,0,0\"\u003e\u003cspan data-path-to-node=\"5,1,1,0,0,0\"\u003eDiagnostic Testing for Multiple Myeloma, Risk Stratification and Follow-up\u003c\/span\u003e\u003cspan data-path-to-node=\"5,1,1,0,0,2\"\u003e.\u003c\/span\u003e\u003c\/p\u003e\r\n\u003c\/li\u003e\r\n \t\u003cli\u003e\r\n\u003cp id=\"p-rc_2abbedc5541507de-173\" data-path-to-node=\"5,1,1,1,0\"\u003e\u003cspan data-path-to-node=\"5,1,1,1,0,0\"\u003eUpdate and Recommendations on Imaging Techniques in Myeloma\u003c\/span\u003e\u003cspan data-path-to-node=\"5,1,1,1,0,2\"\u003e.\u003c\/span\u003e\u003c\/p\u003e\r\n\u003c\/li\u003e\r\n \t\u003cli\u003e\r\n\u003cp id=\"p-rc_2abbedc5541507de-174\" data-path-to-node=\"5,1,1,2,0\"\u003e\u003cspan data-path-to-node=\"5,1,1,2,0,0\"\u003eMRD Testing in Multiple Myeloma\u003c\/span\u003e\u003cspan data-path-to-node=\"5,1,1,2,0,2\"\u003e.\u003c\/span\u003e\u003c\/p\u003e\r\n\u003c\/li\u003e\r\n \t\u003cli\u003e\r\n\u003cp id=\"p-rc_2abbedc5541507de-175\" data-path-to-node=\"5,1,1,3,0\"\u003e\u003cspan data-path-to-node=\"5,1,1,3,0,0\"\u003eNew Risk Stratification in Smoldering and Multiple Myeloma\u003c\/span\u003e\u003cspan data-path-to-node=\"5,1,1,3,0,2\"\u003e.\u003c\/span\u003e\u003c\/p\u003e\r\n\u003c\/li\u003e\r\n \t\u003cli\u003e\r\n\u003cp id=\"p-rc_2abbedc5541507de-176\" data-path-to-node=\"5,1,1,4,0\"\u003e\u003cspan data-path-to-node=\"5,1,1,4,0,0\"\u003eLive Panel Discussion: Diagnosis and Follow Up of Patients\u003c\/span\u003e\u003cspan data-path-to-node=\"5,1,1,4,0,2\"\u003e.\u003c\/span\u003e\u003c\/p\u003e\r\n\u003c\/li\u003e\r\n\u003c\/ul\u003e\r\n\u003c\/li\u003e\r\n \t\u003cli\u003e\r\n\u003cp data-path-to-node=\"5,2,0\"\u003e\u003cb data-path-to-node=\"5,2,0\" data-index-in-node=\"0\"\u003eSmoldering MM and Newly Diagnosed Multiple Myeloma:\u003c\/b\u003e\u003c\/p\u003e\r\n\r\n\u003cul data-path-to-node=\"5,2,1\"\u003e\r\n \t\u003cli\u003e\r\n\u003cp id=\"p-rc_2abbedc5541507de-177\" data-path-to-node=\"5,2,1,0,0\"\u003e\u003cspan data-path-to-node=\"5,2,1,0,0,0\"\u003eManagement of Clinical Significance\/Smoldering Myeloma\u003c\/span\u003e\u003cspan data-path-to-node=\"5,2,1,0,0,2\"\u003e.\u003c\/span\u003e\u003c\/p\u003e\r\n\u003c\/li\u003e\r\n \t\u003cli\u003e\r\n\u003cp id=\"p-rc_2abbedc5541507de-178\" data-path-to-node=\"5,2,1,1,0\"\u003e\u003cspan data-path-to-node=\"5,2,1,1,0,0\"\u003eManagement of Newly Diagnosed MM Transplant Eligible\u003c\/span\u003e\u003cspan data-path-to-node=\"5,2,1,1,0,2\"\u003e.\u003c\/span\u003e\u003c\/p\u003e\r\n\u003c\/li\u003e\r\n \t\u003cli\u003e\r\n\u003cp id=\"p-rc_2abbedc5541507de-179\" data-path-to-node=\"5,2,1,2,0\"\u003e\u003cspan data-path-to-node=\"5,2,1,2,0,0\"\u003eManagement of Newly Diagnosed MM Non-transplant Eligible\u003c\/span\u003e\u003cspan data-path-to-node=\"5,2,1,2,0,2\"\u003e.\u003c\/span\u003e\u003c\/p\u003e\r\n\u003c\/li\u003e\r\n \t\u003cli\u003e\r\n\u003cp id=\"p-rc_2abbedc5541507de-180\" data-path-to-node=\"5,2,1,3,0\"\u003e\u003cspan data-path-to-node=\"5,2,1,3,0,0\"\u003eLive Panel Discussion: How to Manage SMM and NDMM\u003c\/span\u003e\u003cspan data-path-to-node=\"5,2,1,3,0,2\"\u003e.\u003c\/span\u003e\u003c\/p\u003e\r\n\u003c\/li\u003e\r\n\u003c\/ul\u003e\r\n\u003c\/li\u003e\r\n \t\u003cli\u003e\r\n\u003cp data-path-to-node=\"5,3,0\"\u003e\u003cb data-path-to-node=\"5,3,0\" data-index-in-node=\"0\"\u003eRelapsed and Refractory Multiple Myeloma:\u003c\/b\u003e\u003c\/p\u003e\r\n\r\n\u003cul data-path-to-node=\"5,3,1\"\u003e\r\n \t\u003cli\u003e\r\n\u003cp id=\"p-rc_2abbedc5541507de-181\" data-path-to-node=\"5,3,1,0,0\"\u003e\u003cspan data-path-to-node=\"5,3,1,0,0,0\"\u003eOptimal Sequencing for RRMM Patients in their 1st and 2nd Relapse\u003c\/span\u003e\u003cspan data-path-to-node=\"5,3,1,0,0,2\"\u003e.\u003c\/span\u003e\u003c\/p\u003e\r\n\u003c\/li\u003e\r\n \t\u003cli\u003e\r\n\u003cp id=\"p-rc_2abbedc5541507de-182\" data-path-to-node=\"5,3,1,1,0\"\u003e\u003cspan data-path-to-node=\"5,3,1,1,0,0\"\u003eNovel Treatments for MM Besides Cell Therapies and Bispecifics\u003c\/span\u003e\u003cspan data-path-to-node=\"5,3,1,1,0,2\"\u003e.\u003c\/span\u003e\u003c\/p\u003e\r\n\u003c\/li\u003e\r\n \t\u003cli\u003e\r\n\u003cp id=\"p-rc_2abbedc5541507de-183\" data-path-to-node=\"5,3,1,2,0\"\u003e\u003cspan data-path-to-node=\"5,3,1,2,0,0\"\u003eLive Panel Discussion: Sequencing of Therapies in RR MM\u003c\/span\u003e\u003cspan data-path-to-node=\"5,3,1,2,0,2\"\u003e.\u003c\/span\u003e\u003c\/p\u003e\r\n\u003c\/li\u003e\r\n\u003c\/ul\u003e\r\n\u003c\/li\u003e\r\n \t\u003cli\u003e\r\n\u003cp data-path-to-node=\"5,4,0\"\u003e\u003cb data-path-to-node=\"5,4,0\" data-index-in-node=\"0\"\u003eNovel Immune Strategies:\u003c\/b\u003e\u003c\/p\u003e\r\n\r\n\u003cul data-path-to-node=\"5,4,1\"\u003e\r\n \t\u003cli\u003e\r\n\u003cp id=\"p-rc_2abbedc5541507de-184\" data-path-to-node=\"5,4,1,0,0\"\u003e\u003cspan data-path-to-node=\"5,4,1,0,0,0\"\u003eCAR T Cells\u003c\/span\u003e\u003cspan data-path-to-node=\"5,4,1,0,0,2\"\u003e.\u003c\/span\u003e\u003c\/p\u003e\r\n\u003c\/li\u003e\r\n \t\u003cli\u003e\r\n\u003cp id=\"p-rc_2abbedc5541507de-185\" data-path-to-node=\"5,4,1,1,0\"\u003e\u003cspan data-path-to-node=\"5,4,1,1,0,0\"\u003eBispecific T Cell Engagers\u003c\/span\u003e\u003cspan data-path-to-node=\"5,4,1,1,0,2\"\u003e.\u003c\/span\u003e\u003c\/p\u003e\r\n\u003c\/li\u003e\r\n \t\u003cli\u003e\r\n\u003cp id=\"p-rc_2abbedc5541507de-186\" data-path-to-node=\"5,4,1,2,0\"\u003e\u003cspan data-path-to-node=\"5,4,1,2,0,0\"\u003eLive Panel Discussion: Incorporating Novel Immunotherapies in Practice\u003c\/span\u003e\u003cspan data-path-to-node=\"5,4,1,2,0,2\"\u003e.\u003c\/span\u003e\u003c\/p\u003e\r\n\u003c\/li\u003e\r\n\u003c\/ul\u003e\r\n\u003c\/li\u003e\r\n \t\u003cli\u003e\r\n\u003cp data-path-to-node=\"5,5,0\"\u003e\u003cb data-path-to-node=\"5,5,0\" data-index-in-node=\"0\"\u003eSupportive Care:\u003c\/b\u003e\u003c\/p\u003e\r\n\r\n\u003cul data-path-to-node=\"5,5,1\"\u003e\r\n \t\u003cli\u003e\r\n\u003cp id=\"p-rc_2abbedc5541507de-187\" data-path-to-node=\"5,5,1,0,0\"\u003e\u003cspan data-path-to-node=\"5,5,1,0,0,0\"\u003eBone Disease and Renal Failure\u003c\/span\u003e\u003cspan data-path-to-node=\"5,5,1,0,0,2\"\u003e.\u003c\/span\u003e\u003c\/p\u003e\r\n\u003c\/li\u003e\r\n \t\u003cli\u003e\r\n\u003cp id=\"p-rc_2abbedc5541507de-188\" data-path-to-node=\"5,5,1,1,0\"\u003e\u003cspan data-path-to-node=\"5,5,1,1,0,0\"\u003eInfection and Vaccinations\u003c\/span\u003e\u003cspan data-path-to-node=\"5,5,1,1,0,2\"\u003e.\u003c\/span\u003e\u003c\/p\u003e\r\n\u003c\/li\u003e\r\n \t\u003cli\u003e\r\n\u003cp id=\"p-rc_2abbedc5541507de-189\" data-path-to-node=\"5,5,1,2,0\"\u003e\u003cspan data-path-to-node=\"5,5,1,2,0,0\"\u003eLive Panel Discussion: Managing Myeloma Related Complications\u003c\/span\u003e\u003cspan data-path-to-node=\"5,5,1,2,0,2\"\u003e.\u003c\/span\u003e\u003c\/p\u003e\r\n\u003c\/li\u003e\r\n\u003c\/ul\u003e\r\n\u003c\/li\u003e\r\n \t\u003cli\u003e\r\n\u003cp data-path-to-node=\"5,6,0\"\u003e\u003cb data-path-to-node=\"5,6,0\" data-index-in-node=\"0\"\u003eUpdate on Other Plasma Cell Disorders:\u003c\/b\u003e\u003c\/p\u003e\r\n\r\n\u003cul data-path-to-node=\"5,6,1\"\u003e\r\n \t\u003cli\u003e\r\n\u003cp id=\"p-rc_2abbedc5541507de-190\" data-path-to-node=\"5,6,1,0,0\"\u003e\u003cspan data-path-to-node=\"5,6,1,0,0,0\"\u003eWaldenström’s Macroglobulinemia\u003c\/span\u003e\u003cspan data-path-to-node=\"5,6,1,0,0,2\"\u003e.\u003c\/span\u003e\u003c\/p\u003e\r\n\u003c\/li\u003e\r\n \t\u003cli\u003e\r\n\u003cp id=\"p-rc_2abbedc5541507de-191\" data-path-to-node=\"5,6,1,1,0\"\u003e\u003cspan data-path-to-node=\"5,6,1,1,0,0\"\u003eAL Amyloidosis\u003c\/span\u003e\u003cspan data-path-to-node=\"5,6,1,1,0,2\"\u003e.\u003c\/span\u003e\u003c\/p\u003e\r\n\u003c\/li\u003e\r\n \t\u003cli\u003e\r\n\u003cp id=\"p-rc_2abbedc5541507de-192\" data-path-to-node=\"5,6,1,2,0\"\u003e\u003cspan data-path-to-node=\"5,6,1,2,0,0\"\u003eLive Panel Discussion: Managing Other Dysporteinemias\u003c\/span\u003e\u003cspan data-path-to-node=\"5,6,1,2,0,2\"\u003e.\u003c\/span\u003e\u003c\/p\u003e\r\n\u003c\/li\u003e\r\n\u003c\/ul\u003e\r\n\u003c\/li\u003e\r\n \t\u003cli\u003e\r\n\u003cp data-path-to-node=\"5,7,0\"\u003e\u003cb data-path-to-node=\"5,7,0\" data-index-in-node=\"0\"\u003eChallenging Questions in MM:\u003c\/b\u003e\u003c\/p\u003e\r\n\r\n\u003cul data-path-to-node=\"5,7,1\"\u003e\r\n \t\u003cli\u003e\r\n\u003cp id=\"p-rc_2abbedc5541507de-193\" data-path-to-node=\"5,7,1,0,0\"\u003e\u003cspan data-path-to-node=\"5,7,1,0,0,0\"\u003eRelapse After T Cell Redirected Therapies\u003c\/span\u003e\u003cspan data-path-to-node=\"5,7,1,0,0,2\"\u003e.\u003c\/span\u003e\u003c\/p\u003e\r\n\u003c\/li\u003e\r\n \t\u003cli\u003e\r\n\u003cp id=\"p-rc_2abbedc5541507de-194\" data-path-to-node=\"5,7,1,1,0\"\u003e\u003cspan data-path-to-node=\"5,7,1,1,0,0\"\u003eExtramedullary Disease and Plasma Cell Leukemia\u003c\/span\u003e\u003cspan data-path-to-node=\"5,7,1,1,0,2\"\u003e.\u003c\/span\u003e\u003c\/p\u003e\r\n\u003c\/li\u003e\r\n \t\u003cli\u003e\r\n\u003cp id=\"p-rc_2abbedc5541507de-195\" data-path-to-node=\"5,7,1,2,0\"\u003e\u003cspan data-path-to-node=\"5,7,1,2,0,0\"\u003eIncorporating Frailty into Treatment Algorithms for MM\u003c\/span\u003e\u003cspan data-path-to-node=\"5,7,1,2,0,2\"\u003e.\u003c\/span\u003e\u003c\/p\u003e\r\n\u003c\/li\u003e\r\n \t\u003cli\u003e\r\n\u003cp id=\"p-rc_2abbedc5541507de-196\" data-path-to-node=\"5,7,1,3,0\"\u003e\u003cspan data-path-to-node=\"5,7,1,3,0,0\"\u003eLive Panel Discussion\u003c\/span\u003e\u003cspan data-path-to-node=\"5,7,1,3,0,2\"\u003e.\u003c\/span\u003e\u003c\/p\u003e\r\n\u003c\/li\u003e\r\n\u003c\/ul\u003e\r\n\u003c\/li\u003e\r\n\u003c\/ul\u003e\r\n\u003c\/div\u003e","brand":"Meducourse","offers":[{"title":"Default Title","offer_id":43163712782434,"sku":"MED-AMB09727","price":40.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0662\/9549\/6802\/files\/International-Myeloma-Society-Educational-Workshop-in-Belgrade-Serbia-2026.jpg?v=1785419571","url":"https:\/\/meducourse.com\/products\/international-myeloma-society-educational-workshop-in-belgrade-serbia-2026","provider":"Meducourse","version":"1.0","type":"link"}